Skip to content

US · ZVRA · BIOTECHNOLOGY

Zevra Therapeutics, Inc. (ZVRA) intrinsic value and stock valuation

$8.76as of 2026-11-21 · Mkt cap 618.23M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Zevra Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values ZVRA with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from ZVRA’s statements →

Zevra Therapeutics, Inc. Graham Number

Graham Number: $9.73d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Biotechnology Boston, MA 02110 zevra.com

How the business is doing

Fiscal 2012–2025, USD

Revenue
$106.5M+51.6% 5y CAGRd
20122025
Net income
$83.2M
20122025
Free cash flow
-$-2.43M
20122025
Total equity
$154.7M
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2025, USD
20252024202320222021
Revenue$106.5M$23.6M$27.5M$10.2M$28.7M
Operating income-$-4.23M-$-87M-$-49.6M-$-42.56M$7.73M
Net income$83.2M-$-105.51M-$-46.05M-$-26.77M-$-8.55M
EPSd$1.45M-$-2.28M-$-1.3M-$-776.17K-$-287.2K
Operating cash flow-$-1.6M-$-69.67M-$-33.53M-$-18.72M$10.4M
Capital expenditure-$-830K$0.00-$-300K-$-90K-$-100K
Free cash flow-$-2.43M-$-69.67M-$-33.83M-$-18.81M$10.3M
Total assets$284.7M$178.1M$172.3M$115.3M$132.9M
Total debt$63.2M$60.3M$43.8M$18.8M$1.61M
Net debt$800K$26.5M$720K-$-46.69M-$-110.74M
Total equity$154.7M$39.7M$61.9M$75.1M$127.1M
Cash and short-term investments$191M$69.5M$67.7M$82.9M$112.4M
Income statement
20252024202320222021
Revenue$106.5M$23.6M$27.5M$10.2M$28.7M
Cost of revenue$16.5M$7.42M$2.94M$220K$2.06M
Gross profit$90M$16.2M$24.5M$9.94M$26.6M
Research and development expenses$12.7M$42.1M$39.8M$19.8M$10.2M
Selling, general and administrative expenses$77.6M$54.9M$35.1M$15M$8.7M
Other expenses$3.86M$6.24M-$-780K$17.7M$0.00
Operating expenses$94.2M$103.2M$74.1M$52.5M$18.9M
Cost and expenses$110.7M$110.6M$77.1M$52.7M$20.9M
Interest income$6.95M$2.17M$4.54M$1.51M$260K
Interest expense$7.98M$7.35M$1.5M$340K$380K
Depreciation and amortization$4.05M$6.39M$1.01M$940K$260K
Ebitda$98.7M-$-76.4M-$-43.54M-$-25.53M-$-7.89M
Operating income-$-4.23M-$-87M-$-49.6M-$-42.56M$7.73M
Total other income/expenses, net$90.9M-$-3.14M$3.56M$15.8M-$-16.25M
Income before tax$86.7M-$-90.14M-$-46.05M-$-26.8M-$-8.52M
Income tax expense$3.45M$15.4M$0.00-$-30K$30K
Net income$83.2M-$-105.51M-$-46.05M-$-26.77M-$-8.55M
Weighted average shares outstanding$55.3M$46.3M$35.5M$34.5M$29.8M
Weighted average diluted shares outstanding$57.3M$46.3M$35.5M$34.5M$29.8M
Balance sheet
20252024202320222021
Cash and short-term investments$191M$69.5M$67.7M$82.9M$112.4M
Net receivables$23.3M$10.5M$17.4M$8.3M$1.53M
Inventory$1.74M$1.97M$24.1M$0.00$0.00
Total current assets$223M$86M$86.9M$92.8M$115.1M
Property, plant and equipment, net$1.7M$1.01M$1.53M$1.78M$2.02M
Goodwill and intangible assets$11.1M$73.7M$73.9M$0.00$0.00
Long-term investments$47.9M$6.01M$0.00$20M$15.4M
Total non-current assets$61.7M$92.1M$85.4M$22.5M$17.9M
Total assets$284.7M$178.1M$172.3M$115.3M$132.9M
Accounts payable$2.48M$13.1M$14M$3.61M$520K
Short-term debt$420K$420K$38.2M$5.13M$370K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$39.3M$34.1M$73.7M$12M$4.23M
Long-term debt$62.8M$59.9M$5.52M$13.6M$1.24M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$90.8M$104.4M$36.7M$28.2M$1.59M
Capital lease obligations$1.28M$790K$1M$1.32M$1.61M
Total liabilities$130.1M$138.5M$110.5M$40.2M$5.82M
Common stock$10K$10K$0.00$0.00$0.00
Retained earnings-$-422.06M-$-505.29M-$-399.78M-$-353.73M-$-267.03M
Accumulated other comprehensive income (loss)-$-760K$630K-$-40K$110K-$0.00
Total equity$154.7M$39.7M$61.9M$75.1M$127.1M
Total investments$176.5M$41.7M$24.7M$37.4M$15.4M
Total debt$63.2M$60.3M$43.8M$18.8M$1.61M
Net debt$800K$26.5M$720K-$-46.69M-$-110.74M
Cash flow statement
20252024202320222021
Net income$83.2M-$-105.51M-$-46.05M-$-41.54M-$-8.55M
Depreciation and amortization$4.05M$6.39M$1.01M$940K$260K
Stock-based compensation$12.6M$14.9M$5.95M$4.29M$2.44M
Change in working capital-$-26.51M-$-6.64M$5.88M-$-410K-$-360K
Accounts receivable-$-11.98M$6.87M-$-9.08M-$-6.77M$1.05M
Inventory-$-1.3M-$-8.87M$210K$150K$0.00
Accounts payable-$-15.59M-$-3.6M$11.1M$3.13M-$-1.11M
Net cash provided by operating activities-$-1.6M-$-69.67M-$-33.53M-$-18.72M$10.4M
Investments in property, plant and equipment-$-830K$0.00-$-300K-$-90K-$-100K
Acquisitions, net$0.00$0.00-$-30.4M-$-14.09M$0.00
Net cash used for investing activities$18.1M-$-22.16M-$-17.39M-$-36.72M-$-15.52M
Common stock issued$12.4M$64.5M$6.32M$320K$49.3M
Common stock repurchased$0.00$0.00-$-3.45M-$-4.72M-$-2.81M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$12.1M$82.1M$28.5M$8.35M$113.1M
Net change in cash$28.6M-$-9.26M-$-22.42M-$-46.88M$108M
Cash at end of period$62.4M$33.8M$43.1M$65.5M$112.4M
Operating cash flow-$-1.6M-$-69.67M-$-33.53M-$-18.72M$10.4M
Capital expenditure-$-830K$0.00-$-300K-$-90K-$-100K
Free cash flow-$-2.43M-$-69.67M-$-33.83M-$-18.81M$10.3M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Zevra Therapeutics, Inc.

        Zevra Therapeutics, Inc., founded in 2006 and based in Celebration, Florida, is a biopharmaceutical company dedicated to discovering and developing innovative treatments for rare diseases. The company employs its proprietary Ligand Activated Therapy (LAT) technology to create novel prodrug versions of existing FDA-approved medications or to enable new applications for other compounds, primarily addressing serious medical conditions within the United States. Zevra's development pipeline is strategically concentrated on high-unmet-need therapeutic areas, including attention deficit hyperactivity disorder (ADHD), stimulant use disorder, and various rare central nervous system (CNS) conditions, such as idiopathic hypersomnia (IH). Their lead product candidate, KP1077, which is a prodrug of d-methylphenidate (known as serdexmethylphenidate), is currently in Phase II clinical trials for the treatment of both IH and narcolepsy. Another key prodrug candidate, KP879, is also advancing through Phase II studies for stimulant use disorder. In addition to its pipeline, Zevra has successfully secured FDA approval for two products: AZSTARYS, a once-daily treatment for ADHD in patients aged six years and older, and APADAZ, an immediate-release combination product containing benzhydrocodone (a prodrug of hydrocodone) and acetaminophen. The company's product portfolio also includes arimoclomol, and it holds collaboration and licensing agreements with KVK-Tech, Inc. and Commave Therapeutics SA. Formerly known as KemPharm, Inc., the company officially rebranded to Zevra Therapeutics, Inc. in February 2023.

        CEO
        Neil F. McFarlane
        Employees
        61
        Beta
        0.85

        Explore

        Frequently asked questions

        What is the intrinsic value of Zevra Therapeutics, Inc. (ZVRA)?

        Zevra Therapeutics, Inc. (ZVRA) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is ZVRA undervalued?

        ZVRA trades at a price of $8.76 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.